For questions regarding claiming CME Credit, please refer to our FAQ section.

 
           
Post-AHA 2014 Webcast

Program Overview:

Trial reports from the Spring 2014 meetings have muddied the controversies regarding bivalirudin versus heparin for PCI. Both bivalirudin and heparin are Level I recommendations as adjunct anticoagulants during PCI for STEMI. Bivalirudin is recommended over heparin when elevated bleeding risk is present because of the mortality benefit from reduced bleeding events including those that occur periprocedurally. However, bivalirudin’s high cost and increased risk of stent thrombosis remain drawbacks.

This webcast will revisit the collective issue of bivalirudin vs heparin for STEMI PCI.  

Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    


Post-TCT Webcast: Refining TAVR Therapies

Program Overview:

Long-term valve durability, stroke complications, and costs remain important considerations when treating patients with transcatheter aortic valve replacement (TAVR) for aortic stenosis. Currently, Medicare reimbursement in the United States is limited to transfemoral TAVR based on cost-effectiveness data. Also, the risk of stroke persists, with the STS/ACC TVT Registry reporting a 30-day stroke rate of 2.8% in general practice. In this live webcast, four internationally renowned experts will discuss important trial data presented at TCT 2014, which will further illuminate the challenges of stroke, cost, and durability associated with TAVR.

Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    

Post-TCT 2014 Webcast: New Coronary Devices and Approaches – ABSORB, DKCRUSH, and RIBS-IV

Program Overview:

Trial reports from the Spring 2014 meetings have muddied the controversies regarding bivalirudin versus heparin for PCI. Both bivalirudin and heparin are Level I recommendations as adjunct anticoagulants during PCI for STEMI. Bivalirudin is recommended over heparin when elevated bleeding risk is present because of the mortality benefit from reduced bleeding events including those that occur periprocedurally. However, bivalirudin’s high cost and increased risk of stent thrombosis remain drawbacks.

This webcast will revisit the collective issue of bivalirudin vs heparin for STEMI PCI.  

Click Here to access this CME Program    
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour   

Late Breaking Trials from ACC, CIT and EuroPCR:   Bivalirudin vs. Heparin in STEMI

Program Overview:

Trial reports from the Spring 2014 meetings have muddied the controversies regarding bivalirudin versus heparin for PCI. Both bivalirudin and heparin are Level I recommendations as adjunct anticoagulants during PCI for STEMI. Bivalirudin is recommended over heparin when elevated bleeding risk is present because of the mortality benefit from reduced bleeding events including those that occur periprocedurally. However, bivalirudin’s high cost and increased risk of stent thrombosis remain drawbacks.

This webcast will revisit the collective issue of bivalirudin vs heparin for STEMI PCI.  

Click Here to access this CME Program   
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour    


 
DAPT CME Program Overview:

This webcast examines common clinical dilemmas with dual antiplatelet therapy including noncardiac surgeries, DAPT plus anticoagulants for atrial fibrillation patients post-PCI, and managing bleeding complications with DAPT or triple therapy. Clinical tools and recent clinical trial data are discussed to help physicians with decision-making around DAPT.

Click Here to access this CME Program   
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour